Anti-PD-1 Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting anti-pd-1 clinical trials across 1 country. Studies span Phase 2, Phase 1, Phase 3. Top locations include Chongqing, Chongqing Municipality, China, Shanghai, Shanghai Municipality, China, Chengdu, Sichuan, China. Updated daily from ClinicalTrials.gov.


Anti-PD-1 Trials at a Glance

7 actively recruiting trials for anti-pd-1 are listed on ClinicalTrialsFinder across 5 cities. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Chongqing, Shanghai, and Chengdu. Lead sponsors running anti-pd-1 studies include Shanghai Jiao Tong University School of Medicine, The Second Affiliated Hospital of Chongqing Medical University, and Ruijin Hospital.

Browse anti-pd-1 trials by phase

Treatments under study

About Anti-PD-1 Clinical Trials

Looking for clinical trials for Anti-PD-1? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Anti-PD-1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Anti-PD-1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Head and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, School of Medicine, Zhejiang University27 enrolled1 locationNCT07447570
Recruiting
Phase 2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Anti-PD-1 AntibodyChronic Hepatitis B
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05769816
Recruiting
Phase 2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Anti-PD-1 AntibodyChronic Hepatitis BPeg-IFNα
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05771402
Recruiting
Phase 1

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Gastrointestinal TumorsPersonalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
Ruijin Hospital40 enrolled1 locationNCT07067385
Recruiting
Phase 1Phase 2

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal CancerRadiotherapyAnti-PD-1 Antibody+2 more
West China Hospital20 enrolled1 locationNCT04636008
Recruiting
Phase 2

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell CarcinomaNeoadjvant TherapyAnti-PD-1+1 more
Shanghai Jiao Tong University School of Medicine46 enrolled1 locationNCT05069857
Recruiting
Phase 2Phase 3

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

ChemotherapyOral Squamous Cell CarcinomaNeoadjvant Therapy+1 more
Shanghai Jiao Tong University School of Medicine80 enrolled1 locationNCT05125055